Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H11NO3.C5H7NO3 |
| Molecular Weight | 298.2918 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)[C@@H]1CCC(=O)N1.CC2=NC=C(CO)C(CO)=C2O
InChI
InChIKey=RYKKQQUKJJGFMN-HVDRVSQOSA-N
InChI=1S/C8H11NO3.C5H7NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5;7-4-2-1-3(6-4)5(8)9/h2,10-12H,3-4H2,1H3;3H,1-2H2,(H,6,7)(H,8,9)/t;3-/m.0/s1
| Molecular Formula | C8H11NO3 |
| Molecular Weight | 169.1778 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C5H7NO3 |
| Molecular Weight | 129.114 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugs.com/nda/metadoxine_170109.html |
http://www.alcobra-pharma.com/products.cfm?productID=142229 |
https://www.ncbi.nlm.nih.gov/pubmed/1870355
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/nda/metadoxine_170109.html |
http://www.alcobra-pharma.com/products.cfm?productID=142229 |
https://www.ncbi.nlm.nih.gov/pubmed/1870355
Metadoxine is an ion pair salt of pyridoxine and pyrrolidon carboxilate (PCA). Metadoxine is predominantly used in developing nations for acute alcohol intoxication. The positive effect of metadoxine on ethanol metabolism can be explained by the maintenance of normal levels of alcohol dehydrogenase during chronic ethanol intake. Metadoxine was investigated against ADHD, but FDA put hold on phase III clinical trials. Metadoxine is also investigated as a treatment for fragile X synsdome.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2096668 |
|||
Target ID: P41595 Gene ID: 3357.0 Gene Symbol: HTR2B Target Organism: Homo sapiens (Human) |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | VIBOLIV Approved UseThe medication is a hepatoprotective agent, prescribed for the treatment of fatty liver due to alcoholism. |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effects of pyridoxine-pyrrolidon-carboxylate on hepatic and cerebral ATP levels in ethanol treated rats. | 1980 Jun |
|
| Action of metadoxine on isolated human and rat alcohol and aldehyde dehydrogenases. Effect on enzymes in chronic ethanol-fed rats. | 1991 Jan-Feb |
|
| Metadoxine in the treatment of acute and chronic alcoholism: a review. | 2003 Sep-Dec |
Patents
Sample Use Guides
For treatment of fatty liver due to alcoholism, metadoxine could be administered orally, intravenously or intramuscularly. The recommended dose for oral administration is 0.5-1 g/day. The recommended dose for intravenous or intramuscular administration is 300-600 mg/day.
Route of Administration:
Other
The rat stomach fundus bioassay was used to assess the functional activity of metadoxine at the 5-HT2B receptor. For the antagonist assay, ex vivo tissues were repeatedly exposed to a submaximal concentration of the reference agonist 5-carboxamidotryptamine (5-CT, 0.3 μM) to obtain a control contraction, then tissues were washed. This sequence was reproduced at 40-minute intervals in the presence of increasing concentrations of metadoxine (1, 5, 10, and 20 mg/mL) added 30 minutes before the addition of 5-CT
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:19:26 UTC 2023
by
admin
on
Fri Dec 15 19:19:26 UTC 2023
|
| Record UNII |
EJQ7M98H5J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
414513
Created by
admin on Fri Dec 15 19:19:27 UTC 2023 , Edited by admin on Fri Dec 15 19:19:27 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000091630
Created by
admin on Fri Dec 15 19:19:27 UTC 2023 , Edited by admin on Fri Dec 15 19:19:27 UTC 2023
|
PRIMARY | |||
|
DTXSID80996053
Created by
admin on Fri Dec 15 19:19:27 UTC 2023 , Edited by admin on Fri Dec 15 19:19:27 UTC 2023
|
PRIMARY | |||
|
C037845
Created by
admin on Fri Dec 15 19:19:27 UTC 2023 , Edited by admin on Fri Dec 15 19:19:27 UTC 2023
|
PRIMARY | |||
|
115198
Created by
admin on Fri Dec 15 19:19:27 UTC 2023 , Edited by admin on Fri Dec 15 19:19:27 UTC 2023
|
PRIMARY | |||
|
SUB14531MIG
Created by
admin on Fri Dec 15 19:19:27 UTC 2023 , Edited by admin on Fri Dec 15 19:19:27 UTC 2023
|
PRIMARY | |||
|
277-913-8
Created by
admin on Fri Dec 15 19:19:27 UTC 2023 , Edited by admin on Fri Dec 15 19:19:27 UTC 2023
|
PRIMARY | |||
|
Metadoxine
Created by
admin on Fri Dec 15 19:19:27 UTC 2023 , Edited by admin on Fri Dec 15 19:19:27 UTC 2023
|
PRIMARY | |||
|
74536-44-0
Created by
admin on Fri Dec 15 19:19:27 UTC 2023 , Edited by admin on Fri Dec 15 19:19:27 UTC 2023
|
PRIMARY | |||
|
EJQ7M98H5J
Created by
admin on Fri Dec 15 19:19:27 UTC 2023 , Edited by admin on Fri Dec 15 19:19:27 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
